The Saudi Ministry of Health (MOH) has issued an official advisory on 15 October 2025 reaffirming the safety and efficacy of statin cholesterol-lowering drugs. The notice seeks to address widespread misinformation circulating on social media that has prompted some patients to discontinue statin use without medical consultation.
Details of the Advisory
According to the MOH, statins remain internationally and locally approved by the Saudi Food and Drug Authority (SFDA) and are proven to play a critical role in preventing heart disease, stroke, and complications associated with high cholesterol.
The Ministry urged healthcare practitioners to maintain professionalism by refraining from sharing unverified or misleading medical claims. To strengthen enforcement, the General Authority for Media Regulation will implement legal measures against individuals or organizations disseminating false medical information, in close coordination with the MOH.
Why It Matters
This advisory strengthens public confidence in regulatory oversight and pharmaceutical safety in Saudi Arabia. It also highlights the government’s commitment to combating misinformation, ensuring regulatory clarity, and protecting patient health. For healthcare providers and pharmaceutical companies, the directive underscores the importance of verifying medical information, aligning with MOH and SFDA communication standards, and maintaining compliance integrity.
Next Steps
Organizations should:
- Review product labeling and promotional content to ensure compliance with MOH and SFDA guidelines.
- Reassess internal protocols to prevent dissemination of unverified medical information.
- Monitor patient communications for any misconceptions related to statin use and provide appropriate medical guidance.
In this evolving regulatory environment, staying ahead of compliance risks is critical.
RegASK is a leading Agentic AI regulatory intelligence and workflow orchestration platform that empowers global organizations in highly regulated sectors, including life sciences and pharmaceuticals, to proactively navigate complex regulatory landscapes. By combining experts in the loop, RegASK delivers predictive, actionable insights and end-to-end compliance automation, helping teams streamline processes, reduce risk, and accelerate market access across more than 140 countries.
Learn more or book a demo now.
FAQs
What was the purpose of the MOH advisory on statin drugs?
The advisory aimed to reaffirm the safety and effectiveness of statin medications and to counter misinformation that has led some patients to stop using them without medical advice.
Are statins approved in Saudi Arabia?
Yes. Statin drugs are approved by the Saudi Food and Drug Authority (SFDA) and the Ministry of Health, confirming their safety and therapeutic value.
What legal actions can be taken against misinformation spreaders?
The General Authority for Media Regulation, in collaboration with the MOH, will enforce legal measures against individuals or organizations spreading false medical information.
How can RegASK support organizations in managing such advisories?
RegASK enables pharmaceutical and healthcare organizations to track, analyze, and act on regulatory advisories like this one in real time. Its AI-driven regulatory intelligence system ensures teams maintain compliance, prevent misinformation risks, and align communications with MOH and SFDA standards efficiently.
Subscribe to the latest regulatory news
Curated newsletters
Relevant industry info
Access expert insights
